Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 08/01/25
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 07/30/25
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing TherapyBusiness Wire • 07/16/25
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic FibrosisGlobeNewsWire • 07/16/25
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership TransitionGlobeNewsWire • 05/19/25
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous DiseaseGlobeNewsWire • 05/19/25
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/08/25
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 03/18/25
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 02/28/25
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing TherapiesSeeking Alpha • 11/26/24
Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep GenomicsGlobeNewsWire • 11/21/24
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual CongressGlobeNewsWire • 10/24/24
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific MeetingsGlobeNewsWire • 10/15/24